Oral GLP-1 therapeutics advance disease modification across obesity-metabolic syndrome-diabetes continuum

The obesity-metabolic syndrome-diabetes continuum is characterized by interconnected pathologies including insulin resistance, dysfunctional adiposity, and chronic inflammation, leading to progressive cardio-renal-metabolic injury. Current injectable glucagon-like peptide-1 receptor agonists (GLP-1 RAs) offer significant benefits like weight loss, glycemic control, and cardiovascular/renal protection. However, the burden of injections, adherence challenges, and access restrictions often limit their long-term effectiveness. There is a critical need for more convenient, patient-friendly formulations to bridge this treatment gap.

This comprehensive review synthesized the mechanistic rationale, formulation science, and clinical development of oral GLP-1 RAs. Researchers critically discussed biological barriers to oral peptide absorption, such as enzymatic degradation, low epithelial permeability, and pharmacokinetic variability. They evaluated enabling technologies like SNAC-based gastric absorption, nanocarriers, mucoadhesive systems, and stability-optimization platforms. Evidence from the PIONEER program and related studies was synthesized to assess the efficacy, safety, and clinical utility of oral GLP-1 RAs in patients with type 2 diabetes and chronic kidney disease.

The review established oral semaglutide as the first validated proof of concept for systemic peptide delivery via the gastrointestinal route, demonstrating its ability to overcome significant biological barriers. Key challenges identified include enzymatic degradation in the GI tract, low epithelial permeability, and variable pharmacokinetics. Enabling technologies, particularly SNAC (salcaprozate sodium), were highlighted for facilitating gastric absorption by protecting the peptide from degradation and enhancing permeability. The PIONEER program and related studies consistently showed meaningful glycemic and weight-loss efficacy, alongside an acceptable safety profile, in patients with type 2 diabetes and chronic kidney disease. Beyond first-generation platforms, the review explored emerging non-peptide oral GLP-1 RAs, dual and triple incretin agonists, and precision dosing strategies. These advancements signify a shift in oral GLP-1-based therapeutics from a mere formulation breakthrough to a broader translational strategy for disease modification. > Oral semaglutide demonstrated meaningful glycemic control and weight loss, establishing a new paradigm for systemic peptide delivery via the oral route.